Lactobacillus johnsonii La1 NCC533 (CNCM I-1225), non-replicating, and immune disorders

Which composition comprises L. johnsonii La1 (NCC533 Deposit No. CNCM I-1225), for use in the treatment or prevention of disorders related to immune system, wherein a percentage of at least 90%, such as, for example, a percentage of at least 95%, of all of L. johnsonii La1 (NCC533 deposit No. CNCM 1-1225), become non-replicating, treating at a temperature within a range ranging from 110 ° C to 140 ° C for a period of from 5 to 30 seconds, wherein the disorder related to the immune system is selected from the group consisting of infections, in a particular form , bacterial infections, viral infections, fungal infections and / or parasitic infections; inflammations; phagocyte deficiencies; defects epithelial barrier; the immaturity of the immune system; bacterial overgrowth in the small intestine (SIBO)), and combinations thereof, disorders associated with a reduced level of hBDA defensin selected from the group consisting of cystic fibrosis, reactive diseases of the airways (respiratory) , lung infections from the smoking snuff, asthma, pneumonia, rhinitis, otitis, sinusitis, tuberculosis, Crohn's disease (ileum and colon), ulcerative colitis, celiac disease, intestinal immaturity gastritis and gastric ulcer induced by Helicobacter pylori infection, infectious diarrhea, necrotizing enterocolitis, diarrhea associated with antibiotics, bacterial vaginosis, HIV, herpes simplex virus, urinary tract infection, atopic dermatitis , chronic ulcers, carcinoma, atopic eczema, burn injuries, tonsillitis, gingivitis, dental caries, keratitis in the eye s, and combinations thereof